Re-induction with L-DNR/FLAG improves response after AML relapse, but not long-term survival

Area of Science:

• Pediatric Hematology Oncology
• Acute Myeloid Leukemia Research
• Cancer Relapse Therapeutics

Background:

• International studies indicated improved response with L-DNR/FLAG compared to FLAG alone for relapsed AML, but without enhanced survival.
• Findings from the Relapsed AML 2001/01 study suggested potential group-specific variations in treatment efficacy.

Purpose of the Study:

• To analyze patient characteristics, treatment received, and long-term outcomes in pediatric patients with relapsed or primary refractory AML in Germany.
• To evaluate the effectiveness of L-DNR/FLAG versus FLAG re-induction therapy in a German cohort.

Main Methods:

• Retrospective analysis of 155 pediatric patients (first relapse and primary non-responders) treated in Germany.
• Comparison of outcomes between patients receiving L-DNR/FLAG and FLAG re-induction regimens.

Main Results:

• Overall 4-year survival rates were similar between the L-DNR/FLAG (0.43 ± 0.05) and FLAG (0.47 ± 0.06) groups.
• Lower rates of randomization and treatment arm changes were observed, with a preference for L-DNR/FLAG in 40% of cases based on individual decisions.
• The L-DNR/FLAG group had fewer patients with favorable cytogenetics and morphology, while FLAG-treated patients showed a trend towards less favorable initial response and more frequent protocol intensifications.

Conclusions:

• Selection bias favoring patients with unfavorable risk factors in the FLAG group and more intensive treatment in the FLAG arm may have offset the initial benefits of L-DNR/FLAG.
• Similar, relatively favorable survival rates were achieved in both treatment groups within the German cohort, suggesting complex interactions between therapy, patient selection, and treatment intensity.